Complications and Management of Polymethylmethacrylate (PMMA) Injections to the Midface

Roberto Murillo Limongi, Jeremiah Tao, Andre Borba, Filipe Pereira, Ana Rosa Pimentel, Patrícia Akaishi, Antônio Augusto Velasco Cruz

Research output: Contribution to journalArticle

Abstract

Background Polymethylmethacrylate (PMMA) has been used as an injectable filler to treat hollows and reduce rhytids. PMMA injections have been associated with several side effects, however, the literature is scarce on periorbital complications and their treatments. Objectives The purpose of this study is to report a series of complications after periorbital PMMA injections to the midface and to describe their management. Methods Retrospective chart review, including photography and histopathology when available. Results The authors identified 11 cases of complications of PMMA injections to the midface. Patient ages ranged from 36 to 62 years (mean, 47 years; median, 44 years). Two (18%) were males and 9 (82%) were females. Adverse effects began between 2 to 24 months after injection (mean, 7.2 months; median, 6 months). All patients had edema, erythema, and contour irregularity. Seven (64%) patients had nodules, 4 (36%) had yellow, xanthomatous skin changes, and 2 (18%) had eyelid malposition. Histopathology demonstrated a giant cell inflammation in 5 of 6 cases. Corticosteroid injection was tried in 6 cases but was associated with minimal clinical improvement. Surgical debulking of the implanted material was performed in 9 (82%) cases and was effective in improving edema, erythema, and nodularity. Conclusions PMMA injection to the midface may be associated with chronic inflammation, fibrotic nodules, yellowing of the skin, and eyelid malposition. Intralesional corticosteroid injections yielded minimal or no improvement; surgical debulking achieved favorable results. Level of Evidence: 4 Therapeutic.

Original languageEnglish (US)
Pages (from-to)132-135
Number of pages4
JournalAesthetic Surgery Journal
Volume36
Issue number2
DOIs
StatePublished - Feb 1 2016
Externally publishedYes

Fingerprint

Polymethyl Methacrylate
Injections
Eyelids
Erythema
Edema
Adrenal Cortex Hormones
Intralesional Injections
Inflammation
Skin
Photography
Giant Cells
Therapeutics

ASJC Scopus subject areas

  • Surgery

Cite this

Limongi, R. M., Tao, J., Borba, A., Pereira, F., Pimentel, A. R., Akaishi, P., & Velasco Cruz, A. A. (2016). Complications and Management of Polymethylmethacrylate (PMMA) Injections to the Midface. Aesthetic Surgery Journal, 36(2), 132-135. https://doi.org/10.1093/asj/sjv195

Complications and Management of Polymethylmethacrylate (PMMA) Injections to the Midface. / Limongi, Roberto Murillo; Tao, Jeremiah; Borba, Andre; Pereira, Filipe; Pimentel, Ana Rosa; Akaishi, Patrícia; Velasco Cruz, Antônio Augusto.

In: Aesthetic Surgery Journal, Vol. 36, No. 2, 01.02.2016, p. 132-135.

Research output: Contribution to journalArticle

Limongi, RM, Tao, J, Borba, A, Pereira, F, Pimentel, AR, Akaishi, P & Velasco Cruz, AA 2016, 'Complications and Management of Polymethylmethacrylate (PMMA) Injections to the Midface', Aesthetic Surgery Journal, vol. 36, no. 2, pp. 132-135. https://doi.org/10.1093/asj/sjv195
Limongi RM, Tao J, Borba A, Pereira F, Pimentel AR, Akaishi P et al. Complications and Management of Polymethylmethacrylate (PMMA) Injections to the Midface. Aesthetic Surgery Journal. 2016 Feb 1;36(2):132-135. https://doi.org/10.1093/asj/sjv195
Limongi, Roberto Murillo ; Tao, Jeremiah ; Borba, Andre ; Pereira, Filipe ; Pimentel, Ana Rosa ; Akaishi, Patrícia ; Velasco Cruz, Antônio Augusto. / Complications and Management of Polymethylmethacrylate (PMMA) Injections to the Midface. In: Aesthetic Surgery Journal. 2016 ; Vol. 36, No. 2. pp. 132-135.
@article{e9906d93de974518b280462c50b71bd1,
title = "Complications and Management of Polymethylmethacrylate (PMMA) Injections to the Midface",
abstract = "Background Polymethylmethacrylate (PMMA) has been used as an injectable filler to treat hollows and reduce rhytids. PMMA injections have been associated with several side effects, however, the literature is scarce on periorbital complications and their treatments. Objectives The purpose of this study is to report a series of complications after periorbital PMMA injections to the midface and to describe their management. Methods Retrospective chart review, including photography and histopathology when available. Results The authors identified 11 cases of complications of PMMA injections to the midface. Patient ages ranged from 36 to 62 years (mean, 47 years; median, 44 years). Two (18{\%}) were males and 9 (82{\%}) were females. Adverse effects began between 2 to 24 months after injection (mean, 7.2 months; median, 6 months). All patients had edema, erythema, and contour irregularity. Seven (64{\%}) patients had nodules, 4 (36{\%}) had yellow, xanthomatous skin changes, and 2 (18{\%}) had eyelid malposition. Histopathology demonstrated a giant cell inflammation in 5 of 6 cases. Corticosteroid injection was tried in 6 cases but was associated with minimal clinical improvement. Surgical debulking of the implanted material was performed in 9 (82{\%}) cases and was effective in improving edema, erythema, and nodularity. Conclusions PMMA injection to the midface may be associated with chronic inflammation, fibrotic nodules, yellowing of the skin, and eyelid malposition. Intralesional corticosteroid injections yielded minimal or no improvement; surgical debulking achieved favorable results. Level of Evidence: 4 Therapeutic.",
author = "Limongi, {Roberto Murillo} and Jeremiah Tao and Andre Borba and Filipe Pereira and Pimentel, {Ana Rosa} and Patr{\'i}cia Akaishi and {Velasco Cruz}, {Ant{\^o}nio Augusto}",
year = "2016",
month = "2",
day = "1",
doi = "10.1093/asj/sjv195",
language = "English (US)",
volume = "36",
pages = "132--135",
journal = "Aesthetic Surgery Journal",
issn = "1090-820X",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Complications and Management of Polymethylmethacrylate (PMMA) Injections to the Midface

AU - Limongi, Roberto Murillo

AU - Tao, Jeremiah

AU - Borba, Andre

AU - Pereira, Filipe

AU - Pimentel, Ana Rosa

AU - Akaishi, Patrícia

AU - Velasco Cruz, Antônio Augusto

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Background Polymethylmethacrylate (PMMA) has been used as an injectable filler to treat hollows and reduce rhytids. PMMA injections have been associated with several side effects, however, the literature is scarce on periorbital complications and their treatments. Objectives The purpose of this study is to report a series of complications after periorbital PMMA injections to the midface and to describe their management. Methods Retrospective chart review, including photography and histopathology when available. Results The authors identified 11 cases of complications of PMMA injections to the midface. Patient ages ranged from 36 to 62 years (mean, 47 years; median, 44 years). Two (18%) were males and 9 (82%) were females. Adverse effects began between 2 to 24 months after injection (mean, 7.2 months; median, 6 months). All patients had edema, erythema, and contour irregularity. Seven (64%) patients had nodules, 4 (36%) had yellow, xanthomatous skin changes, and 2 (18%) had eyelid malposition. Histopathology demonstrated a giant cell inflammation in 5 of 6 cases. Corticosteroid injection was tried in 6 cases but was associated with minimal clinical improvement. Surgical debulking of the implanted material was performed in 9 (82%) cases and was effective in improving edema, erythema, and nodularity. Conclusions PMMA injection to the midface may be associated with chronic inflammation, fibrotic nodules, yellowing of the skin, and eyelid malposition. Intralesional corticosteroid injections yielded minimal or no improvement; surgical debulking achieved favorable results. Level of Evidence: 4 Therapeutic.

AB - Background Polymethylmethacrylate (PMMA) has been used as an injectable filler to treat hollows and reduce rhytids. PMMA injections have been associated with several side effects, however, the literature is scarce on periorbital complications and their treatments. Objectives The purpose of this study is to report a series of complications after periorbital PMMA injections to the midface and to describe their management. Methods Retrospective chart review, including photography and histopathology when available. Results The authors identified 11 cases of complications of PMMA injections to the midface. Patient ages ranged from 36 to 62 years (mean, 47 years; median, 44 years). Two (18%) were males and 9 (82%) were females. Adverse effects began between 2 to 24 months after injection (mean, 7.2 months; median, 6 months). All patients had edema, erythema, and contour irregularity. Seven (64%) patients had nodules, 4 (36%) had yellow, xanthomatous skin changes, and 2 (18%) had eyelid malposition. Histopathology demonstrated a giant cell inflammation in 5 of 6 cases. Corticosteroid injection was tried in 6 cases but was associated with minimal clinical improvement. Surgical debulking of the implanted material was performed in 9 (82%) cases and was effective in improving edema, erythema, and nodularity. Conclusions PMMA injection to the midface may be associated with chronic inflammation, fibrotic nodules, yellowing of the skin, and eyelid malposition. Intralesional corticosteroid injections yielded minimal or no improvement; surgical debulking achieved favorable results. Level of Evidence: 4 Therapeutic.

UR - http://www.scopus.com/inward/record.url?scp=84969961376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969961376&partnerID=8YFLogxK

U2 - 10.1093/asj/sjv195

DO - 10.1093/asj/sjv195

M3 - Article

C2 - 26446059

AN - SCOPUS:84969961376

VL - 36

SP - 132

EP - 135

JO - Aesthetic Surgery Journal

JF - Aesthetic Surgery Journal

SN - 1090-820X

IS - 2

ER -